Page 25 - 74_01

VOL. 74 (1), 5-27, 2008 ARILESTERASA. ASPECTOS METODOLÓGICOS...

(37) a risk factor for coronary heart disease in type 2 diabetic patients. Diabetes.
49: 1390-1393.
(38) FORTUNATO, G.; RUBBA, P.; PANICO, S.; TRONO, D.; TINTO, N.; MAZZACCARA, C; DE
(39) MICHELE, M.; IANUZZI, A.; VITALE, D. F.; SALVATORE, F. and SACHETTI, L. (2003):
A paraoxonase gene polymorphism, PON1 (55), as an independent risk factor
(40) for increased carotid intima-media thickness in middle-aged women. Athe-
(41) rosclerosis. 167: 141-148.
MACKNESS, B.; MACKNESS, M. I.; ARROL, S.; TURKIE, W. and DURRINGTON, P. N.
(1997): Effect of the molecular polymorphisms of human paraoxonase
(PON1) on the rate of hydrolysis of paraoxon. Br. J. Pharmacol. 122: 265–268.
NUS, M.; FRANCES, F.; SÁNCHEZ-MONTERO, J. M.; CORELLA, D. and SÁNCHEZ-MUNIZ,
F. J. (2006): Arylesterase activity and HDL-cholesterol levels are dependent
on the PON55M and PON192R polymorphisms. International Symposium
on Atherosclerosis. Roma (Comunicación oral publicada en Atherosclerosis
Suppl 2006; 7: 333).
ECKERSON, H. W.; ROMSON, J.; WYTE, C. and LA DU, B. N. (1983): The human
serum paraoxonase/arylesterase polymorphism. Am. J. Human Genet. 35:
214-227.
NUS, M.; SÁNCHEZ-MUNIZ, F. J. and SÁNCHEZ-MONTERO, J. M. (2006): A new
method for the determination of arylesterase activity in human serum using
Simulated Body Fluid. Atherosclerosis. 188: 155-159.

27